Heckler M, Gallo R: Press Conference. 1984, Available at: http://youtu.be/k6zd3gdDKG8,
Google Scholar
Wainberg W: Ten big challenges ahead. BMC Infect Dis. 2014, 14 (Suppl 2): S1
Article
PubMed Central
Google Scholar
Gulick R: New ARV drugs. BMC Infect Dis. 2014, 14 (Suppl 2): S2
Article
PubMed Central
Google Scholar
Boffito M: Development of long-acting ARVs. BMC Infect Dis. 2014, 14 (Suppl 2): S11
Article
PubMed Central
Google Scholar
Nelson M: First-line therapy in 2014. BMC Infect Dis. 2014, 14 (Suppl 2): S3
Article
PubMed Central
Google Scholar
Clumeck N, Mwamba C, Kabeya K, Vincent C, Serge M, Dolorès V, Gilles P, Coca N, Marc D, David K, Chantal M, Joe I, Liévin K: First-line therapy with LPV/r vs NVP and 2 NRTIs in a developing country: W144 of a randomized trial. BMC Infect Dis. 2014, 14 (Suppl 2): 02-
Article
Google Scholar
Podzamer D: Switch strategies in 2014. BMC Infect Dis. 2014, 14 (Suppl 2): S4
Article
Google Scholar
Miedema F, Hazenberg MD, Tesselaar K, van Baarle D, de Boer RJ, Borghans JA: Immune activation and collateral damage in AIDS pathogenesis. Front Immunol. 2013, 4: 298-doi:10.3389/fimmu.2013.00298,
Article
PubMed Central
PubMed
Google Scholar
Mallon PW: Aging with HIV: osteoporosis and fractures. Curr Opin HIV AIDS. 2014, 9 (4): 428-435. doi:10.1097/COH.0000000000000080,
Article
PubMed
Google Scholar
Peters B: ARV regimen choice and co = morbidities. BMC Infect Dis. 2014, 14 (Suppl 2): S9
Article
PubMed Central
Google Scholar
Lichtenstein K: Statin use in setting of HIV infection. BMC Infect Dis. 2014, 14 (Suppl 2): S10
Article
PubMed Central
Google Scholar
Hussen SA, Andes K, Gilliard D, Chakraborty R, Del Rio C, Malebranche DJ: Transition to adulthood and antiretroviral adherence among HIV-positive young black men who have sex with men. Am J Public Health. 2014, 12: e1-e7. [Epub ahead of print],
Google Scholar
Supervie V: Improving prevention and early diagnosis. BMC Infect Dis. 2014, 14 (Suppl 2): S6-
Article
PubMed Central
Google Scholar
Cohen MS: ART for prevention: opportunities, challenges and predictions. BMC Infect Dis. 2014, 14 (Suppl 2): S7-
Article
PubMed Central
Google Scholar
Lange J: Implementation of TasP challenges and opportunities. BMC Infect Dis. 2014, 14 (Suppl 2): S8-
Article
PubMed Central
Google Scholar
Shan L: Update on HIV reservoirs. BMC Infect Dis. 2014, 14 (Suppl 2): S18-
Article
PubMed Central
Google Scholar
Rasmussen TA, Tolstrup M, Winckelmann A, Østergaard L, Søgaard OS: Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother. 2013, 9 (4): 790-799.
Article
PubMed Central
CAS
PubMed
Google Scholar
Lutzen JV: Gene therapy and bone marrow transplantation. BMC Infect Dis. 2014, 14 (Suppl 2): S19-
Article
Google Scholar
Hauber J, Karpinski J, Iauber I, Chemnitz J, Hofmann-Sieber H, Nagel CH, Beschorner N, Schäfer C, Buchholz F: Next generation LTR specific Tre-recombinase targets a majority of HIV-1 isolates. BMC Infect Dis. 2014, 14 (Suppl 2): 018-
Article
Google Scholar
Gatignol A, Scarborough RH, Levesque MV, Boudrias-Dalle E, ChuteI C, Daniels SM, Ouellette RJ, Perreault J-P: Towards gene therapy against HIV-1: new therapeutic target in gag RNA accessible to ribozymes and RNA interference molecules. BMC Infect Dis. 2014, 14 (Suppl 2): 019-
Article
Google Scholar
Czernekova L, Raska M, Moldoveanu Z, Zachova K, Hall S, Badalova D, Krcmarska A, Hana Synkoval H, Hoelscher M, Maboko L, Brown R, Novak Z, Mestecky J, Novak J: Differential glycosylation of envelope gp120 affects reactivity with HIV-1 specific antibodies. BMC Infect Dis. 2014, 14 (Suppl 2): 68-
Article
Google Scholar
Girard M: Is an HIV vaccine achievable?. BMC Infect Dis. 2014, 14 (Suppl 2): S14-
Article
PubMed Central
Google Scholar
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, : Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009, 361 (23): 2209-2220.
Article
CAS
PubMed
Google Scholar
Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong G, Louder MK, Longo NS, McKee K, Nonyane M, O’Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK: Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014, 509: 55-62.
Article
PubMed Central
CAS
PubMed
Google Scholar
Su B, Moog C: Which antibody functions are important for an HIV vaccine?. Front Immunol. 2014, 5: 289-
Article
PubMed Central
PubMed
Google Scholar
Padane A, Camara M, Seydi M, Jennes W, Diallo AA, Fall A, Diaw PA, Sow PS, Mboup S, Kestens L, Dieye TN: Resistance to HIV-1 infection among HIV-exposed seronegative partners in HIV-discordant couples is associated with higher frequency of CD8+ T cells expressing CD107a and b molecules. BMC Infect Dis. 2014, 14 (Suppl 2): 67-
Article
Google Scholar
Hua S, Lecuroux C, Saez-Cirion A, Pancino G, Girault I, Sinet M, Lambotte O, Venet A: The potential role of HIV-specific CD38-/HLA-DR + CD8+ T cells in viral suppressive activity and cytotoxicity in HIV controllers. BMC Infect Dis. 2014, 14 (Suppl 2): 64-
Article
Google Scholar
Hauber L, Schulze zur Wiesch J, Schuhmacher U, Schäfer C, van Lunzen J, Hauber J: Personalizing humanized mice with cells obtained from an HIV post treatment controller. BMC Infect Dis. 2014, 14 (Suppl 2): 36-
Article
Google Scholar
Stamatatos L, Morris L, Burton DR, Mascola JR: Neutralizing antibodies generated during natural HIV infection: good news for an HIV vaccine?. Nat Med. 2009, 15 (8): 866-870.
CAS
PubMed
Google Scholar
West AP, Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC: Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell. 2014, 156: 633-648.
Article
PubMed Central
CAS
PubMed
Google Scholar
Slavcev R, Sum Nafissi N: Optimized production of a safe and efficient gene therapeutic vaccine versus HIV via a linear covalently closed DNA minivector. BMC Infect Dis. 2014, 14 (Suppl 2): 74-
Article
Google Scholar
Selbovitz M, Miller D: In vivo analysis of GenePro, a lentivral therapeutic vaccine. BMC Infect Dis. 2014, 14 (Suppl 2): 2-
Article
Google Scholar
Bauche C, Rodriguez M, Sarry E, Bejanariu A, Sabbah-Petrover E: Lentiviral-based anti-HIV therapeutic vaccine: design, preclinical studies and phaseI/II clinical trial preliminary results. BMC Infect Dis. 2014, 14 (Suppl 2): 81-
Article
Google Scholar
Caruso A, Laria M, Caccuri F, Giagulli C, Fiorentini S: Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study. BMC Infect Dis. 2014, 14 (Suppl 2): O6-
PubMed Central
Google Scholar
Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, An DS, Baltimore D: Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med. 2014, 20: 296-300.
Article
PubMed Central
CAS
PubMed
Google Scholar
Zagury D, Bernard J, Halbreich A, Bizzini B, Carelli C, Achour A, Defer MC, Bertho JM, Lanneval K, Zagury JF: One-year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: a new strategy. J Acquir Immune Defic Syndr. 1992, 5 (7): 676-681.
CAS
PubMed
Google Scholar
Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X, Robinson JE, Seaman MS, Fouts TR, Gallo RC, DeVico AL, Lewis GK: Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A. 2013, 110 (1): E69-E78.
Article
PubMed Central
CAS
PubMed
Google Scholar
Asselah T, Marcellin P: Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 2012, 32 (Suppl 1): 88-102.
Article
CAS
PubMed
Google Scholar
Schinazi R, Halfon P, Marcellin P, Asselah T: HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014, 34 (Suppl 1): 69-78.
Article
CAS
PubMed
Google Scholar
Halfon P, Cacoub P: Treatment of hepatitis C with new direct antiviral drugs: towards a disease cure. Rev Med Interne. 2014, 35: 219-221.
Article
CAS
PubMed
Google Scholar
Feeney ER, Chung RT: Antiviral treatment of hepatitis C. BMJ. 2014, 349: g3308-
Article
Google Scholar
Rockstroh JK: Managing HCV infection: present and future. BMC Infect Dis. 2014, 14 (Suppl 2): S5-
Article
PubMed Central
Google Scholar
Zoulim F: New anti-HCV agents in the pipeline. BMC Infect Dis. 2014, 14 (Suppl 2): S15-
Article
PubMed Central
Google Scholar
Soriano V: Treatment of hepatitis C in HIV patients in the new DAA era. BMC Infect Dis. 2014, 14 (2): S16-
Article
PubMed Central
Google Scholar
Bourlière M: HCV cure without interferon. BMC Infect Dis. 2014, 14 (2): S17-
Article
PubMed Central
Google Scholar
Dalton H: Hepatitis E. BMC Infect Dis. 2014, 14 (Suppl 2): S20-
Article
PubMed Central
Google Scholar
Lina B: H7N9 flu. BMC Infect Dis. 2014, 14 (Suppl 2): S21-
Article
PubMed Central
Google Scholar
Müller M: MERS-CoV. BMC Infect Dis. 2014, 14 (Suppl 2): S22-
Article
PubMed Central
Google Scholar
Simon F, Ferraro J, Javelle E, Marimoutou C: Chikungunya infection: six years after, rheumatic morbidity and impaired quality of life persist!. BMC Infect Dis. 2014, 14 (2): O21-
Article
PubMed Central
Google Scholar
Javelle E, Ribera A, Degasne I, Marimoutou C, Simon F: Clinical spectrum of post-chikungunya rheumatic musculoskeletal disorders and use of disease-modifying antirheumatic drugs to treat the chronic inflammatory entities: 6-year experience from Reunion Island. BMC Infect Dis. 2014, 14 (Suppl 2): O20-
Article
PubMed Central
Google Scholar